Supernus Pharmaceuticals, Inc. (SUPN) News Headlines

▮ More

Date

Headline

5/2/2022 5:18:31 PM FDA Approves Supernus Pharmaceuticals' Qelbree For Treatment Of ADHD In Adults

5/2/2022 8:55:08 AM Supernus Pharma: FDA Approves Expanded Indication For Qelbree - Quick Facts

5/2/2022 8:32:38 AM Supernus: FDA Approves Expanded Indication For Qelbree For Treatment Of Attention Deficit Hyperactivity Disorder

5/2/2022 8:30:00 AM Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults (Press Release)

3/28/2022 1:31:43 AM Biotech Stocks Facing FDA Decision In April 2022

12/8/2021 8:49:08 AM Supernus Resubmits NDA For SPN-830 Apomorphine Infusion Device For Treatment Of Motor Fluctuations In PD

10/11/2021 6:53:47 AM Supernus Pharma To Acquire Adamas Pharma For Total Consideration Up To $9.10/shr

10/11/2021 6:35:55 AM Supernus To Acquire Adamas Through Tender Offer For $8.10/Shr Cash

4/2/2021 10:12:18 PM FDA Approves Supernus's Qelbree For Treatment Of Attention-deficit Hyperactivity Disorder

11/11/2014 5:32:53 PM Supernus Pharmaceuticals, Inc. (SUPN) Has Raised Its FY14 Revenue Estimate To $115 - $118 Mln From $105 Mln

10/22/2012 7:09:33 AM Supernus Pharma Obtains FDA Approval For Oxtellar XR In Epilepsy - Quick Facts

6/26/2012 9:44:14 AM Supernus Pharma's Epilepsy Drug Gets FDA's Tentative Approval; Shares Soar

6/11/2012 5:20:08 AM Supernus Pharma: Inching Closer To FDA Decision

Older Articles